ArticleJournal of endocrinology, diabetes & obesity
Safety and Efficacy of D-Tagatose in Glycemic Control in Subjects with Type 2 Diabetes.
Article in Journal of endocrinology, diabetes & obesity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Effects of D-Tagatose on Cariogenic Risk: A Systematic Review of Randomized Clinical Trials.Nutrients · 2025Pooled it
- The effects of low-calorie sweeteners on energy intake and body weight: a systematic review and meta-analyses of sustained intervention studies.International journal of obesity (2005) · 2021Pooled it
- Non-nutritive sweeteners for diabetes mellitus.The Cochrane database of systematic reviews · 2020Pooled it
- Acute Effects of Nutritive and Non-Nutritive Sweeteners on Postprandial Blood Pressure.Nutrients · 2019Pooled it
- The Effect of Small Doses of Fructose and Its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials.Nutrients · 2018Pooled it
- Quantification of Monosaccharides in Blood and Urine by HPAEC-PAD.Journal of agricultural and food chemistry · 2026Article
- Identification of FGF21-inducing rare sugars that reduces sugar appetite in male BL/6 mice.Physiological reports · 2025Article
- Metabolic Deficiencies in the Vitreous of Diabetic Retinopathy: Exploring the Potential of Dietary Supplementation to Address Key Metabolite Imbalances.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- D-Tagatose: A Rare Sugar with Functional Properties and Antimicrobial Potential against Oral Species.Nutrients · 2024Review
- In Vitro Anti-Diabetic, Anti-Inflammatory, Antioxidant Activities and Toxicological Study of OptimizedPharmaceuticals (Basel, Switzerland) · 2023Article
- Trends in lactose-derived bioactives: synthesis and purification.Systems microbiology and biomanufacturing · 2022Review
- D-Tagatose Feeding Reduces the Risk of Sugar-Induced Exacerbation of Myocardial I/R Injury When Compared to Its Isomer Fructose.Frontiers in molecular biosciences · 2021Article
- Natural Alternative Sweeteners and Diabetes Management.Current diabetes reports · 2019Review
- Reduced Susceptibility to Sugar-Induced Metabolic Derangements and Impairments of Myocardial Redox Signaling in Mice Chronically Fed with D-Tagatose when Compared to Fructose.Oxidative medicine and cellular longevity · 2018Article
- D-Tagatose Is a Promising Sweetener to Control Glycaemia: A New Functional Food.BioMed research international · 2018Review
- BSN723T Prevents Atherosclerosis and Weight Gain in ApoE Knockout Mice Fed a Western Diet.WebmedCentralArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The primary objectives of this study were to evaluate the treatment effect of D-tagatose on glycemic control, determined by a statistically significant decrease in hemoglobin A1c (HbA1c), and safety profile of D-tagatose compared to placebo. The secondary objectives were to evaluate the treatment effects on fasting blood glucose, insulin, lipid profiles, changes in BMI, and the proportion of subjects achieving HbA1c targets of <7%. Type 2 diabetic patients not taking any blood glucose lowering medications were administered either 15 g of D-tagatose dissolved in 125-250 ml of water three times a day or placebo with meals. Reduction in HbA1c was statistically significant compared to placebo at all post-baseline time points in the ITT population. Additionally, secondary endpoints were achieved in the ITT population with regard to LDL, total cholesterol, fasting blood glucose, and proportion of subjects achieving HbA1c targets of <7%. D-tagatose was unable to lower triglycerides or raise HDL compared to placebo. A subgroup LOCF analysis on the ITT US population showed a greater and statistically significant LS mean reduction in HbA1c in the D-tagatose group at all post-baseline visits. Based on these results it is concluded that in the ITT population D-tagatose is an effective single agent at treating many of the therapy targets of type 2 diabetes including lowering fasting blood glucose and HbA1c, and lowering of LDL and total cholesterol.
Indexed as
Identifiers
27054147PMC4820068W2419178907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.